机译:病毒抑制与0.5mg和1.0mg日常剂量的恩替卡韦在治疗 - 朴素的HBV相关的失代偿性肝硬化中相当。
Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences;
Department of Gastroenterology King George's Medical University;
Department of Gastroenterology Dr Ram Manohar Lohia Institute of Medical Sciences;
Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences;
Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences;
Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences;
Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences;
机译:对每天服用1.0 mg恩替卡韦有部分反应的患者对更高剂量的恩替卡韦1.0 mg的反应
机译:恩替卡韦在初治乙肝病毒相关失代偿性肝硬化患者中的疗效。
机译:初治慢性乙型肝炎患者连续三年恩替卡韦治疗:病毒抑制,病毒抵抗和临床安全性。
机译:低剂量的Balsalazide(每日两次1.5克)和美沙拉嗪(0.5 g每天三次)可维持溃疡性结肠炎的缓解但是高剂量的Balsalazide(3.0 g每天两次)可预防复发
机译:针对HBV相关肝细胞癌和病毒DNA患者的围手术期Entecavir:使用倾向得分匹配分析